Document:

Exhibit 10.3

 

SUPPLEMENTAL
AGREEMENT

 

This
Supplemental Agreement (the “Supplemental Agreement”) of the Deed of Rights Transfer, Strategic Partnership
and Undertaking Agreement is made and entered into on November 10, 2020 (“Effective Date”) by and between:

 

	 	(1)	Regencell
Bioscience limited, a limited liability company
incorporated in Hong Kong, whose business address is at 11/F First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong
Kong; (the “Company”); and

 

	 	(2)	Mr.
Sik-Kee Au, the holder of Hong Kong Identity Card No. ********, being the Listed Chinese Medicine Practitioner with the Listed
No. L05*** maintained by the Chinese Medicine Practitioners Board of the Chinese Medicine Council of Hong Kong (the “TCM
Practitioner”).

 

Company
and TCM Practitioner are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
All terms not herein defined shall have the meaning given to them in the Partnership Agreement (as defined below).

 

Recitals:

 

WHEREAS,
the Company is an early stage bioscience company that focuses on research, development, and commercialization of Traditional Chinese
Medicine (“TCM”) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity
Disorder (“ADHD”) and Autism Spectrum Disorder (“ASD”);

 

WHEREAS,
The TCM Practitioner has been practicing TCM under the guidance of the Chinese Medicine Ordinance (Chapter 549 of the Laws of
Hong Kong) and has accumulated over thirty years of research and clinical practice experience.;

 

WHEREAS,
the Parties have entered Deed of Rights Transfer, Strategic Partnership and Undertaking agreement (the “Partnership Agreement”)
on January 1, 2018, pursuant to which the TCM Practitioner transfers his legal and beneficial ownership of the intellectual property
rights of the his TCM Formulae and TCM Inventions and the Company undertakes to pay for all costs and expenses incurred by the
TCM Practitioner in his research, testing, attending meetings/seminars, compiling records/reports or performing any similar acts
in relation to the development of his TCM Formulae. Unless the context otherwise requires, words defined in the Partnership Agreement
shall have the same meaning in this Supplemental Agreement. The rules of interpretation set out in the Partnership Agreement shall
apply to this Supplemental Agreement;

 

WHEREAS,
the Parties desire to enter this Supplemental Agreement to provide the terms and conditions upon which the TCM Practitioner accepts
the supervisions and direction of the Company on his TCM Formulae research, non-competition, and the non-disclosure restrictions
in his practice under the Partnership Agreement.

 

    1

     

    

 

NOW,
THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants, agreements, representations, warranties
and indemnities and conditions contained in this Supplemental Agreement, and for other good and valuable consideration, the receipt
and sufficiency of which are acknowledged by the Parties, the Parties agree as follows:

 

		1.	Definitions

 

		1.1	“Affiliate”
means (i) all business units and divisions of a party or its parent company/corporation and (ii) any entity controlled by,
controlling, or under common control with such party. Such entity shall be deemed to be an “Affiliate” only so long
as such control exists.

 

		1.2	“Applicable
Laws” means all applicable laws, treaties, statutes, codes, rules, regulations, regulatory policies, practices, guidelines,
ordinances, judgments, orders, rulings or decisions of any governmental authorities and other pronouncements having the effect
of law of any national, multinational, city or other political subdivision, domestic or foreign, in each case binding on or applicable
to a Party referred to in the context in Hong Kong.

 

		1.3	“Business”
means all business and affiliates carried out by the Company and its Affiliates from time to time, including but not limited to
the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically
ADHD and ASD.

 

		1.4	“Confidential
Information” means all information, know-how and records (in whatever form held) in any way connected with the Company,
its Business and the Research, whether proprietary or otherwise, including (without prejudice to the generality of the foregoing)
without limitation all TCM Inventions, TCM Formulae, the intellectual property rights, designs, specifications, drawings, data,
operations and testing procedures, manuals and instructions and all customer, patient, and supplier information and lists, sales
information, business plans and methods, processes, systems, research and development, forecasts and all technical or other expertise,
and all accounting and tax records, correspondence, orders and enquiries that are confidential or not generally known.

 

Confidential
Information shall include information in written, oral, electronic or any other form whether or not it is clearly identified in
writing at the time of disclosure as confidential. For avoidance of doubt, Confidential Information shall not include information
that (i) is or becomes a part of the public domain through no act or omission of the other Party; (ii) was in the other Party’s
lawful possession prior to the disclosure and had not been obtained by the other Party either directly or indirectly from the
disclosing Party; (iii) is lawfully disclosed to the other Party by a third party without restriction on disclosure; or (iv) is
independently developed by the other Party without use of or reference to the other Party’s Confidential Information.

 

		1.5	“Research”
means all services, materials, products, TCM Formulae, TCM Inventions, or intellectual property provided, developed, and researched
by TCM Practitioner to the Company and its Affiliates under this Supplemental Agreement and the Partnership Agreement or as otherwise
agreed by the Parties from time to time.

 

		1.6	“Results”
means all data and information generated or derived from the Research and from other research performed by the TCM Practitioner
under this Supplemental Agreement and Partnership Agreement, including but not limited to new TCM Formulae, TCM Inventions, and
intellectual property.

 

		2.	Scope
of the Supplemental Agreement

 

		2.1	TCM
Practitioner shall perform the Research, in accordance with the terms and conditions of this Supplemental Agreement. TCM Practitioner
shall use reasonable efforts to perform the Research and to meet all standards, obligations and completion dates described in
this Supplemental Agreement or to be agreed by the Parties.

 

		2.2	The
Company has full discretion to assign, refine, update or redesign tasks of the Research to the TCM Practitioner from time-to-time.
Such instructions and changes shall be effective upon notice to TCM Practitioner.

 

		2.3	TCM
Practitioner shall provide the Research in accordance with the terms and conditions set forth in this Supplemental Agreement and
all Applicable Laws.

 

		2.4	Upon
request by the Company, which shall be made from time to time, TCM Practitioner shall transfer all: (i) Results, and/or (ii) any
other materials, data, information and all other data it possesses with regard to each Research to the Company, in such form as
requested by the Company or as is then currently in the possession of TCM Practitioner.

 

    2

     

    

 

		3.	Research

 

		3.1	TCM
Practitioner may assign appropriately qualified personnel to perform any and some of the Research with the Company’s prior
written consent (the “Development Team”). The Development Team shall use high professional standards while
performing the Research and maintaining full compliance with any and all specification and instructions set by the Company from
time to time.

 

		3.2	TCM
Practitioner shall protect, promote and act in the best interests of the Company, including but not limited to:

 

		(i)	devote
the whole of his attention and skill to the interests and affairs of the Company in the discharge of the Research;

 

		(ii)	in
the discharge of the Research and in the exercise of such powers, comply with all and any lawful directions and instructions from
time to time made or given to him by the Company according to the best of his skills and ability, and comply with all resolutions
and regulations from time to time passed or made by the Company;

 

		(iii)	faithfully
and diligently perform the Research with due care and skill, and exercise only such powers as are consistent with the Research
in relation to, and use commercially reasonable efforts to promote, the interests of the Company;

 

		(iv)	keep
the Company promptly and fully informed of his and the Development Team’s conduct of the Research and give promptly to the
Company (in writing if so requested) all such information as the Company may reasonably require in relation to its conduct of
the Research insofar as such information is or ought to be within the knowledge of TCM Practitioner and provide such written explanations
to the Company may require in connection therewith; and

 

		(v)	use
commercially reasonable efforts to ensure that they are available at all times on reasonable notice to provide the Research as
the Company may require.

 

		3.3	TCM
Practitioner shall not subcontract or delegate the performance of all or part of the Research to any personnel other than the
Development Team, without written consent given by the Company.

 

		4.	Research
Fees and Payment

 

		4.1	In
consideration of due performance of TCM Practitioner’s obligations under this Supplemental Agreement and Partnership Agreement,
TCM Practitioner shall be entitled to receive with effect from the Effective Date during the Term (defined hereunder) a research
fee covering all costs and expenses incurred by the TCM Practitioner in conducting research, testing, attending meetings/seminars,
compiling records/reports or performing any similar acts in relation to the development of the TCM Invention, TCM Formulae and
all intellectual property rights  (including any tax and duties payable by TCM Practitioner pursuant to the Applicable Laws
and any compensation rights that TCM Practitioner may have as a result of his compliance with Clause 7 hereunder) (“Research
Fee”).

 

		4.2	TCM
Practitioner shall issue an invoice of Research Fees to the Company on monthly basis. The Research Fee shall be due within thirty
(30) days from the date of the invoice.

 

		4.3	The
Company shall only be responsible for retaining and discharging, and paying Research Fee that are the reasonable fees, charges
and expenses related to the performance of the Research incurred by the TCM Practitioner.

 

		4.4	Payment
of such Research Fees to TCM Practitioner shall be made by the Company. Payment in full or in part of the Research Fees shall
be without prejudice to any claims or rights of the Company against TCM Practitioner in respect of the provision of the Research.

 

		4.5	All
Research Fees are inclusive of taxes, charges or remittance fees. Each Party shall pay any and all tax due under Applicable Laws
by such Party in respect of all payments it receives or makes under this Supplemental Agreement. Each Party shall be solely responsible
for the payment of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under
this Supplemental Agreement and the Partnership Agreement.

 

    3

     

    

 

		4.6	All
payments due under this Supplemental Agreement and the Partnership Agreement to TCM Practitioner shall be made via check or bank
wire transfer which is notified by TCM Practitioner in advance in immediately available funds to a bank account designated by
the TCM Practitioner, free and clear of any withholding tax, administrative fees, bank charges, transfer fees or other similar
charges under the Applicable Laws.

 

		5.	Representations
and Warranties

 

		5.1	Each
Party represents, warrants and covenants to the other Party that:

 

		(i)	each
Party has taken all actions to authorize the execution, delivery and performance of the obligations undertaken in this Supplemental
Agreement, and no other corporate actions are necessary with respect thereto; and

 

		(ii)	when
executed and delivered by it, this Supplemental Agreement will constitute a legal, valid and binding obligation of it, enforceable
against it in accordance with this Supplemental Agreement’s terms.

 

		5.2	The
TCM Practitioner further represents and warrants to the Company that as of the Effective Date and at all times during the Term
of the Supplemental Agreement:

 

		(i)	the
Supplemental Agreement has been duly executed and delivered by, and is the legal and valid obligations upon TCM Practitioner and
the entry into, the execution and delivery of, and the carrying out and other performance of its obligations under this Supplemental
Agreement by TCM Practitioner: (a) does not conflict with, or contravene or constitute any default under, any agreement, instrument
or understanding, oral or written, to which he is a party, and (b) does not violate Applicable Laws;

 

		(ii)	TCM
Practitioner shall not enter into any other agreements which would interfere with or prevent the performance of the obligations
described herein;

 

		(iii)	TCM
Practitioner maintains and shall maintain during the Term of this Supplemental Agreement equipment and personnel sufficient to
enable him to perform the Research in accordance with the Supplemental Agreement;

 

		(iv)	the
TCM Formulae, TCM Inventions, and its intellectual property rights to be developed in the future under the Partnership Agreement
by the TCM Practitioner will be original, and will not be subject to any third party’s rights or claims; the TCM Formulae,
TCM Inventions and its intellectual property rights will not be published, in whole or part, without the Company’s prior
written consent;

 

		(v)	no
third party shall acquire, own, or possess any right or interest in any TCM Formulae, TCM Inventions, and its intellectual property
rights to be developed in the future that arises out of or is made as a consequence of any Research by TCM Practitioner pursuant
to this Supplemental Agreement and Partnership Agreement.

 

    4

     

    

 

		6.	Confidentiality;
Non-Disclosure

 

		6.1	The
TCM Practitioner, his agents, subcontractors, development team, and Affiliates shall, during or after the Term, directly or indirectly
publish, disseminate or otherwise disclose, deliver or make available to any third party any Confidential Information, without
prior written notice given by the Company. The TCM Practitioner shall use the Confidential Information solely for the purpose(s)
set forth in this Supplemental Agreement, the Partnership Agreement, or for such other purposes as may be agreed upon by the Parties
in writing. The confidentiality obligations under this Clause 6 shall survive notwithstanding the termination of this Supplemental
Agreement for ten (10) years thereafter.

 

		6.2	The
TCM Practitioner, his agents, subcontractors, development team, and Affiliates undertake to use the Confidential Information only
for the fulfilment of the Research, and shall not at any time:

 

		(i)	divulge
or communicate to any person any Confidential Information except those of the employees of the Company or the third party without
the Company’s prior written consent; and

 

		(ii)	through
any failure to exercise all due care and diligence cause any unauthorized disclosure of any Confidential Information (including
without limitation): relating to the Research, dealings, organization, business, finance, transactions or any other affairs of
the Company.

 

		6.3	The
TCM Practitioner agrees, on behalf of himself, his agents, subcontractors, development team and Affiliates, not to publish or
present any and all information, data and/or documents, whether patentable or not, as generated in the course of and/or as a result
of the Research.

 

		6.4	The
TCM Practitioner shall not disclose the terms herein of this Supplemental Agreement and the Partnership Agreement and/or any relationship
between TCM Practitioner and the Company to any third party.

 

		7.	Restraint
on Activities of TCM Practitioner; Non-Competition

 

		7.1	During
the Term, TCM Practitioner undertakes and shall cause himself to undertake to the Company that he will devote his time and attention
to the Company and will use his best endeavors to develop the business and interests of the Company and will not be concerned
with any other business other than the Business.

 

		7.2	For
two (2) years after the expiration or termination of this Supplemental Agreement, whichever is earlier, the TCM Practitioner shall
not be directly or indirectly concerned with or engaged or interested in any other business which is in any respect in competition
with or similar to the Business conducted by the Company.

 

		8.	Term;
Termination

 

		8.1	Unless
otherwise earlier terminated pursuant to this Clause 8.2-8.4, this Supplemental Agreement shall be effective on the Effective
Date and shall remain effective until the Partnership Agreement is expired or terminated (“Term”). In the event
that both Parties agree to extend the Term or to renew this Supplemental Agreement, the Parties may do so by executing a separate
written agreement or extension or renewal.

 

		8.2	The
Company may terminate this Supplemental Agreement for any reason in the Company’s sole discretion and without any indemnity
or damages being due to TCM Practitioner with thirty (30) days prior written notice.

 

		8.3	In
addition, the Company may terminate this Supplemental Agreement:

 

		(i)	upon
any breach by TCM Practitioner of his obligations under this Supplemental Agreement which is not cured within thirty (30) days
of the notification of such; and

 

    5

     

    

 

		(ii)	immediately
if TCM Practitioner is no longer able to perform the Research; commits any act of gross or willful misconduct or any serious,
willful, grossly negligent or material breach of any of the provisions contained in this Supplemental Agreement; commits any fraud
or act of dishonesty, engages in any conduct which, in the reasonable opinion of the Company, has caused or is likely to cause
detriment to the interests of the Company, is otherwise prohibited by Applicable Laws from providing the Research, refuses to
carry out any reasonable lawful order given to TCM Practitioner by the Company in the Term, is incompetent or fail to diligently
attend to the Research.

 

		8.4	The
TCM Practitioner may terminate this Supplemental Agreement in the event that the Company fails to meet its payment obligations
under Clause 4.2 of this Supplemental Agreement which is not cured within thirty (30) days of the notification of such by the
Company.

 

		8.5	Upon
expiration or termination of this Supplemental Agreement, the TCM Practitioner shall:

 

		(i)	immediately
deliver to the Company all Confidential Information and all other property of or relating to the Company which may then be in
TCM Practitioner’s possession or under TCM Practitioner’s power or control and all copies thereof or extracts therefrom;
and

 

		(ii)	immediately
delete all Confidential Information from any computer discs, USB devices, tapes or other re-useable material in TCM Practitioner’s
possession or control and destroy all other documents and tangible items in TCM Practitioner’s possession or under TCM Practitioner’s
control which contain or refer to any Confidential Information.

 

		8.6	Termination
of this Supplemental Agreement shall not limit either Party from pursuing other remedies available to it, including injunctive
relief. For the avoidance of doubt, if the Supplemental Agreement hereunder is terminated by Company for cause, Company shall
not be obligated to continue making any additional Research Fees as of the date of termination.         8.7
In the event of expiration or termination of this Supplemental Agreement, Clauses 1, 6, 7, 8.5-8.7, 9 and 10, as well as any provisions
which are to survive by nature, shall survive such expiration or termination.

 

		9.	Governing
Law and Jurisdiction

 

		9.1	This
Supplemental Agreement is governed by and shall be construed in all respects in accordance with the laws of Hong Kong.

 

		9.2	Any
dispute, controversy, difference or claim arising out of or relating to this Supplemental Agreement, including the existence,
validity, interpretation, performance, breach or termination thereof or any dispute regarding non-contractual obligations arising
out of or relating to it shall be referred to and finally resolved by arbitration administered by the Hong Kong International
Arbitration Centre (HKIAC) under the HKIAC Administered Arbitration Rules in force when the Notice of Arbitration is submitted.
The arbitration proceeding shall be conducted in Hong Kong. There shall be three (3) arbitrators, each Party shall appoint one
(1) arbitrator and the third arbitrator shall be jointly appointed by the appointed arbitrators.

 

		10.	Miscellaneous

 

		10.1 	This
Supplemental Agreement, and the rights and obligations hereunder, may not be assigned or transferred by either Party without prior
written consent of the other Party, except that Company may assign this Supplemental Agreement to an Affiliate or in connection
with a merger, consolidation or sale of all or substantially all of its assets.

 

		10.2 	Unless
otherwise provided in this Supplemental Agreement, no changes, amendments or alternations to this Supplemental Agreement shall
be allowed unless in writing and are signed by duly authorized representatives of both Parties.

 

    6

     

    

 

		10.3 	In
the event that any one or more of the provisions contained in this Supplemental Agreement, shall for any reason, be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions
of this Supplemental Agreement and the Partnership Agreement, and all other provisions in this Supplemental Agreement and the
Partnership Agreement shall remain in full force and effect. If any of the provisions of this Supplemental Agreement are held
to be excessively broad, it shall be reformed and construed by limiting and reducing it so as to be enforceable to the maximum
extent permitted by the Applicable Laws.

 

		10.4 	Neither
Parties shall be held liable for nonfulfillment or delayed performance of this Supplemental Agreement or of part thereof due directly
or indirectly to any cause outside the defaulting Party’s control, provided that notice of its inability to perform and
the causes thereof shall be given immediately by the affected Party to the other.

 

		10.5 	This
Supplemental Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which,
when taken together, shall constitute one original instrument.

 

		10.6 	Headings
to clauses herein are for the convenience of the parties only and are not intended to be or to affect the meaning or interpretation
of this Supplemental Agreement.

 

		10.7 	All
notice, requests, demands, approvals or consents, or other communications hereunder shall be in writing and shall be deemed given
if delivered: (i) by electronic mail stated below, (ii) by registered mail with acknowledgement of receipt, or (iii) personally
to the appropriate party at the address below:

 

	 	If to the Company:
	 	 
	 	Address:	11/F First Commercial Building	 
	 	 	33-35 Leighton Road	 
	 	 	Causeway Bay, Hong Kong	 
	 	Email:	 	 
	 	Attention:	Mr. Yat-Gai Au	 
	 	 	 	 
	 	If to TCM Practitioner:
	 	 
	 	Address:	22/F First Commercial Building	 
	 	 	33-35 Leighton Road	 
	 	 	Causeway Bay, Hong Kong	 
	 	Email:	 	 
	 	Attention:	Mr. Sik-Kee Au	 

 

[Signature
page to follow]

 

    7

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Supplemental Agreement in two (2) originals by their respective officers duly
authorized as of the Effective Date.

 

	Regencell bioscience limited
	 	 	 
	/s/ Yat-Gai Au	 
	Name:	Yat-Gai Au	 
	Title:	Chief Executive Officer	 
	 	 	 
	 	 	 
	sik-kee au
	 	 	 
	/s/ Sik-Kee Au	 
	Name:	Sik-Kee Au	 
	Title:	TCM Practitioner	 

 

 

8Exhibit 10.4

 

LOAN AGREEMENT

 

entered
into between:

 

Mr.
Yat-Gai Au

(“the Lender”)

 

And

 

Regencell
Bioscience Limited

(“the Borrower”)

 

This
LOAN AGREEMENT (hereinafter referred to as the “Agreement”) is made and entered into on November 10,
2020, by and between Yat-Gai Au, a holder of Hong Kong Identity Card Number: P*******, 11/F First Commercial Building, 33-35 Leighton
Road, Causeway Bay, Hong Kong (hereinafter referred to as the “Lender”) and Regencell Bioscience Limited, a
limited company duly established under the laws of Hong Kong, having its registered office at 11/F First Commercial Building,
33-35 Leighton Road, Causeway Bay, Hong Kong (hereinafter referred to as the “Borrower”). The Lender and the
Borrower collectively shall be referred to as the “Parties” and respectively as the “Party.”

 

WHEREAS,
immediately prior to effectiveness of this Agreement, the Lender has provided certain loans to the Borrower in an aggregate amount
of HK$23,945,298 as of June 30, 2020 and an additional HK$3,634,387 from July 1, 2020 to November 10, 2020. (the “Existing
Loan”);

 

WHEREAS,
the Parties desire to enter this Agreement to evidence the Existing Loan and document their oral agreements of the terms and conditions
of such Existing Loan when such loan was initially generated; and

 

WHEREAS,
the Lender further agrees to make Loan (as defined below) to the Borrower in connection with the daily operation and research
of the Borrower in accordance with the terms and conditions set forth in this Agreement;

 

NOW
THEREFORE, the Parties agree as follows:

 

Article
1 – Definitions and interpretation

 

		1.1	Definitions;
In this Agreement, the following expressions shall have the following meanings:

 

“Business
Day” means a day (other than a Saturday, Sunday or public holiday) on which commercial banks are open for normal banking
business in Hong Kong.

 

“Effective
Date” means the date this Agreement is signed upon by both parties as mentioned in the beginning of this Agreement.

 

“Loan”
means the loan facility made available in HK dollar, without limit on the number or duration, through wire transfer to Borrower’s
bank account upon the effectiveness of this Agreement.

 

“Loan
Date” means the Business Day on which the Lender makes available the Loan to the Borrower.

 

“Maturity
Date” means the 30th day of June 2021, subject to indefinite extension if agreed by the Parties in writing.

 

“Tax”
means any tax, levy, impost, duty or other charge or withholding of a similar nature (including any related penalty or interest).

 

    1

     

    

 

		1.2	Interpretation;
In this Agreement, unless the context otherwise requires:

 

a.
headings and underlining are for convenience only and shall not affect the interpretation of this Agreement;

 

b.
words importing the singular shall include the plural and vice versa;

 

c.
words importing a gender shall include any gender; and

 

d.
references to “HK$” or “HK dollar” shall refer to the official currency of Hong Kong.

 

Article
2 –  The Loan

 

		2.1	Loan;
Subject to the terms of this Agreement, the Lender agrees to make the Loan available to the Borrower in a timely manner or make
payments on the Borrower’s behalf, according to the needs of the operations and research activities of the Borrower and
its subsidiaries or parent company.

 

		2.2	Purpose
of the Loan; The Loan is strictly for the use by the Borrower and its subsidiaries or parent company for daily operation
and research activities. The use of Loan shall be agreed and determined by the Parties before granting the Loan.

 

Article
3 – Interest

 

		3.1	Interest
Rate; The Loan and Existing Loan shall bear 0% interest per annum.

 

Article
4 – Payment of the Loan and Existing Loan

 

		4.1	Payment;
The Borrower shall repay the Loan and Existing Loan on the Maturity Date. If agreed by the Parties in writing, the Maturity Date
may be extended indefinitely.

 

		4.2	Prepayment;
The Borrower may repay, at any time and from time to time and any other sum then due to the Lender under any provisions of this
Agreement, in whole or in part.

 

		4.3	Method
of Payment; Payment by the Borrower shall be denominated in HK dollar or any other denomination agreed upon by the Parties
and shall be made by telegraphic transfer to such bank and bank account as the Lender shall designate in writing.

 

Article
5 – Taxes

 

The
Borrower shall be responsible for the payment of all present or future taxes and/or duties assessed or imposed by the Government
of Hong Kong or a governmental agency thereof with respect to the execution and/or performance of this Agreement and the repayment
of the Loan.

 

Article
6 – Assignment

 

The
Lender shall be entitled to assign or transfer any of his rights or obligations under this Agreement to a third party by providing
the Borrower with a 7-day prior written notice. The Borrower shall not assign any of its rights or obligations under this Agreement
to any party without the prior written approval by the Lender.

 

Article
7 – Amendment

 

Any
provision of this Agreement may be amended or supplemented only if the Parties so agree in writing.

 

Article
8 – Costs and Expenses

 

Save
as otherwise provided, each Party shall bear its own legal and other costs and expenses incurred in relation to the preparation,
execution, performance or enforcement of this Agreement.

 

    2

     

    

 

Article
9 – Notices

 

Any
notice under this Agreement shall be given in writing by first class pre-paid post and be addressed:

 

If
to the Lender:

 

Mr.
Yat-Gai Au

Address:
11/F First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong

 

If
to the Borrower:

 

Regencell
Bioscience Limited

Address:
11/F First Commercial Building, 33-35 Leighton Road, Causeway Bay, Hong Kong

 

Notices
addressed as provided above shall be deemed to have been duly given when delivered (in the case of personal delivery), 2 (two)
days after posting (in the case of letters sent within the same country), or 5 (five) days after posting (in the case of letters
sent internationally), provided that notices to the Lender shall be effective only upon their actual receipt by the Lender. In
each of the above cases any notice received on a non-working day or after business hours in the country of receipt shall be deemed
to be given on the next following day in such country.

 

Article
10 - Miscellaneous 

 

		10.1 	Governing
Law; This Agreement is subject to and is to be construed in accordance with the laws for the time being and from time
to time in force in Hong Kong.

 

		10.2 	Dispute
Settlement; Any dispute arising out of or in connection with this Agreement, including any question regarding its existence,
validity or termination, shall be referred to and finally resolved by arbitration in Hong Kong in accordance with the Arbitration
Rules of the Hong Kong International Arbitration Centre for the time being in force, which rules are deemed to be incorporated
by reference in this clause. The Tribunal shall consist of three (3) arbitrator(s). The language of the arbitration shall be English.

 

		10.3 	Counterparts;
This Agreement may be executed in counterparts.

 

IN
WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first written above.

 

	Lender	 	Borrower
	Yat-Gai Au 	 	Regencell Bioscience Limited
	 	 	 	 	 
	

/s/ Yat-Gai Au

	 	

/s/ Yat-Gai Au

	Name: 	Yat-Gai Au	 	Name:	Yat-Gai Au
	 	 	 	Title: 	Chairman
    and Chief Executive Officer

 

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00324-of-00352.parquet"}]]